Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney disease?
Open Access
- 21 February 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (4) , sfae039
Abstract
We are entering a new era in the management of adiposity-based chronic disease (ABCD) with type 2 diabetes (T2D) and related chronic kidney disease (CKD). ABCD, T2D and CKD can affect almost every major organ system and have a particularly strong impact on the incidence of cardiovascular disease (CVD) and heart failure. ABCD and the associated insulin resistance are at the root of many cardiovascular, renal and metabolic (CKM) disorders, thus an integrated therapeutic framework using weight loss (WL) as a disease-modifying intervention could simplify the therapeutic approach at different stages across the lifespan. The breakthrough of highly effective WL drugs makes achieving a WL of >10% possible, which is required for a potential T2D disease remission as well as for prevention of microvascular disease, CKD, CVD events and overall mortality. The aim of this review is to discuss the link between adiposity and CKM conditions as well as placing weight management at the centre of the holistic CKM syndrome approach with a focus on CKD. We propose the clinical translation of the available evidence into a transformative Dysfunctional Adipose Tissue Approach (DATA) for people living with ABCD, T2D and CKD. This model is based on the interplay of four essential elements (i.e. adipocentric approach and target organ protection, dysfunctional adiposity, glucose homeostasis, and lifestyle intervention and de-prescription) together with a multidisciplinary person-centred care. DATA could facilitate decision-making for all clinicians involved in the management of these individuals, and if we do this in a multidisciplinary way, we are prepared to meet the adipocentric challenge.Keywords
This publication has 94 references indexed in Scilit:
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityJAMA, 2024
- MR Assessed Changes of Renal Sinus Fat in Response to Glucose Regulation in West European and South Asian Patients With Type 2 DiabetesJournal of Magnetic Resonance Imaging, 2023
- Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 DiabetesJAMA, 2023
- The Fatty Kidney and Beyond: A Silent EpidemicThe American Journal of Medicine, 2023
- Evidence-based European recommendations for the dietary management of diabetesDiabetologia, 2023
- A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamusAppetite, 2022
- Minimal-Dose Resistance Training for Improving Muscle Mass, Strength, and Function: A Narrative Review of Current Evidence and Practical ConsiderationsSports Medicine, 2021
- Spatial mapping reveals human adipocyte subpopulations with distinct sensitivities to insulinCell Metabolism, 2021
- Renal Lipid Metabolism and Lipotoxicity in DiabetesThe American Journal of the Medical Sciences, 2020
- Association of Bariatric Surgery With Long-term Remission of Type 2 Diabetes and With Microvascular and Macrovascular ComplicationsJAMA, 2014